BiotechTube

FAI Insert administered using the Mk II inserter + FAI Insert administered using the Mk I inserter

Phase 3Completed
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non-Infectious Uveitis

Conditions

Non-Infectious Uveitis

Trial Timeline

Feb 23, 2016 → Aug 17, 2017

NCT ID
NCT02748512

About FAI Insert administered using the Mk II inserter + FAI Insert administered using the Mk I inserter

FAI Insert administered using the Mk II inserter + FAI Insert administered using the Mk I inserter is a phase 3 stage product being developed by EyePoint Pharmaceuticals for Non-Infectious Uveitis. The current trial status is completed. This product is registered under clinical trial identifier NCT02748512. Target conditions include Non-Infectious Uveitis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT02748512Phase 3Completed

Competing Products

10 competing products in Non-Infectious Uveitis

See all competitors
ProductCompanyStageHype Score
AdalimumabAbbVieApproved
85
LFG316 + Conventional TherapyNovartisPhase 2
52
AIN457 + PlaceboNovartisPhase 3
77
AIN457 + AIN457 + AIN457 + PlaceboNovartisPhase 3
77
AIN457 + AIN 457 + AIN457NovartisPhase 2
52
ESK-001AlumisPhase 2
47
Topical Prednisolone Acetate 1%Ocular TherapeutixApproved
80
FAI insert + Sham injectionEyePoint PharmaceuticalsPhase 3
72
ADX-102 Ophthalmic Solution (0.5%) + Vehicle of ADX-102 Ophthalmic SolutionAldeyra TherapeuticsPhase 3
69
NS2 + Prednisolone acetate ophthalmic suspension (1%)Aldeyra TherapeuticsPhase 2
44

Other Products from EyePoint Pharmaceuticals

Dexycu + Standard of Care post operative eye drops (steroid, antibiotic, NSAID)Approved
80
Dexamethasone + Prednisolone Acetate OphthalmicApproved
80
DexycuPhase 3
72
FAI insert + Sham injectionPhase 3
72
Sham Injector + FAI InsertPhase 3
72